Aptinyx Inc. (APTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
APTX POWR Grades
- Growth is the dimension where APTX ranks best; there it ranks ahead of 55.88% of US stocks.
- APTX's strongest trending metric is Growth; it's been moving down over the last 31 weeks.
- APTX's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).
APTX Stock Summary
- The ratio of debt to operating expenses for Aptinyx Inc is higher than it is for about just 0.53% of US stocks.
- With a price/sales ratio of 100.29, Aptinyx Inc has a higher such ratio than 96.61% of stocks in our set.
- Revenue growth over the past 12 months for Aptinyx Inc comes in at -51.43%, a number that bests merely 6.45% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Aptinyx Inc are CUE, ACRS, MDGS, FGEN, and XAIR.
- APTX's SEC filings can be seen here. And to visit Aptinyx Inc's official web site, go to www.aptinyx.com.
APTX Valuation Summary
- In comparison to the median Healthcare stock, APTX's price/sales ratio is 2783.33% higher, now standing at 103.8.
- APTX's price/sales ratio has moved up 2.6 over the prior 38 months.
- APTX's price/sales ratio has moved up 2.6 over the prior 38 months.
Below are key valuation metrics over time for APTX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| APTX | 2021-07-06 | 110.8 | 1.3 | -3.9 | -0.9 |
| APTX | 2020-12-22 | 92.8 | 2.1 | -4.4 | -2.4 |
| APTX | 2020-06-17 | 51.8 | 1.5 | -3.4 | -1.2 |
| APTX | 2020-05-14 | 47.8 | 1.4 | -3.1 | -0.9 |
| APTX | 2019-12-04 | 35.4 | 1.2 | -2.3 | -0.3 |
| APTX | 2018-12-17 | 113.0 | 4.4 | -20.3 | -15.5 |
APTX Price Target
For more insight on analysts targets of APTX, see our APTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $10.29 | Average Broker Recommendation | 1.44 (Moderate Buy) |
APTX Stock Price Chart Interactive Chart >
APTX Price/Volume Stats
| Current price | $2.51 | 52-week high | $6.47 |
| Prev. close | $2.57 | 52-week low | $2.30 |
| Day low | $2.49 | Volume | 118,859 |
| Day high | $2.58 | Avg. volume | 800,913 |
| 50-day MA | $2.81 | Dividend yield | N/A |
| 200-day MA | $3.21 | Market Cap | 171.12M |
Aptinyx Inc. (APTX) Company Bio
Aptinyx Inc. develops therapeutics for neurological disorders. The company is focused on the development of drugs that interact with the NMDA receptor, and the company says it will use the funds to advance drugs for chronic pain, post-traumatic stress disorder (PTSD) and cognitive impairment in Parkinson’s disease. The company was founded in 2015 and is based in Evantson, Illinois.
Latest APTX News From Around the Web
Below are the latest news stories about Aptinyx Inc that investors may wish to consider to help them evaluate APTX as an investment opportunity.
Aptinyx to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021EVANSTON, Ill., July 26, 2021--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, August 10, 2021 at 5:00 p.m. ET to report second quarter 2021 financial results and discuss recent business highlights. |
Aptinyx: CNS Drug Discoverer With Depressed PriceDesign Cells/iStock via Getty Images There are various NMDA receptor modulators, but Aptinyx (APTX) is aiming to modulate NMDA receptors at a unique domain distinct from existing drugs, potentially improving on existing therapies. The company hypothesizes that this can produce optimal modulation of NMDARs, avoiding either overactivation or inhibition. Aptinyx... |
Aptinyx Stock Looks Promising If You’re Willing to Be PatientWhen you're shopping for ground-floor biotech opportunities, it pays to be patient and diligent. |
Aptinyx to Participate in William Blair Biotech Focus Conference 2021EVANSTON, Ill., July 12, 2021--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the Updates in Neuropysch panel discussion at the William Blair Biotech Focus Conference on Thursday, July 15 at 12:00 p.m. ET. |
Aptinyx to Participate in Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry SummitEVANSTON, Ill., July 06, 2021--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that management will participate in a fireside chat at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on Tuesday, July 13 at 3:40 p.m. ET. A live webcast of the event will be available to clients of Cowen. |
APTX Price Returns
| 1-mo | -11.31% |
| 3-mo | -6.34% |
| 6-mo | -27.87% |
| 1-year | -36.29% |
| 3-year | -88.55% |
| 5-year | N/A |
| YTD | -27.46% |
| 2020 | 1.17% |
| 2019 | -79.32% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching APTX
Want to see what other sources are saying about Aptinyx Inc's financials and stock price? Try the links below:Aptinyx Inc (APTX) Stock Price | Nasdaq
Aptinyx Inc (APTX) Stock Quote, History and News - Yahoo Finance
Aptinyx Inc (APTX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...